Sigyn Therapeutics annual gross margin
2014
2015
2018
2019
Sigyn Therapeutics's gross margin was 75.12% for fiscal 2019.
View full Sigyn Therapeutics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2019 | 2019-12-31 | 75.12% | +9.38 pp |
| 2018 | 2018-12-31 | 65.74% | −0.26 pp |
| 2015 | 2015-12-31 | 66.00% | +24.51 pp |
| 2014 | 2014-12-31 | 41.49% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q3 2020 | 2020-09-30 | 53.08% | −20.76 pp |
| Q1 2020 | 2020-03-31 | 65.21% | −12.53 pp |
| Q4 2019 | 2019-12-31 | 70.50% | −15.50 pp |
| Q3 2019 | 2019-09-30 | 75.05% | −24.95 pp |
| Q2 2019 | 2019-06-30 | 73.84% | +15.66 pp |
| Q1 2019 | 2019-03-31 | 77.74% | +16.21 pp |
| Q3 2018 · Sep 30 | 2018-09-30 | 86.00% | +28.84 pp |
| Q2 2018 · Jun 30 | 2018-06-30 | 100.00% | +28.26 pp |
| Q1 2018 · Mar 31 | 2018-03-31 | 58.18% | −4.24 pp |
| Q3 2018 · Sep 30 | 2017-09-30 | 61.53% | −0.88 pp |
| Q2 2018 · Jun 30 | 2017-06-30 | 57.17% | −14.96 pp |
| Q1 2018 · Mar 31 | 2017-03-31 | 71.74% | +6.66 pp |
| Q3 2015 | 2015-09-30 | 62.42% | — |
| Q2 2015 | 2015-06-30 | 62.42% | — |
| Q1 2015 | 2015-03-31 | 72.13% | — |
| Q3 2014 | 2014-09-30 | 65.08% | — |
Across the available reported history, Sigyn Therapeutics's gross margin increased from 65.74% to 75.12%, a change of +9.38 percentage points. The latest reported quarter, Q3 2020, shows 53.08%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sigyn Therapeutics filings at SEC.gov ↗